[Omalizumab: What have we learned after ten years of prescription?].
BACKGROUND
Omalizumab, an anti-immunoglobulin E monoclonal antibody, has now been used for ten years as an add-on therapy for severe adult atopic asthma, poorly controlled by high-doses inhaled steroids and long-acting beta-agonists.


BACKGROUND
This innovative therapy has been the first biotherapy used on a large scale in severe asthma. It has shown clinical benefits, especially in the prevention of severe exacerbation, with a satisfactory safety profile. Despite its cost, it is an interesting alternative to continuous oral steroids, which cause more long-term side effects.


CONCLUSIONS
After ten-years of prescription of omalizumab, we review here the mechanism of action, the benefits, the main side effects, the cost-effectiveness and also the alternative indications of this interesting molecule. We also consider the practicalities of using omalizumab, particularly the importance a rigorous assessment of its efficacy after 16 weeks of treatment, and possible future therapeutic indications.


CONCLUSIONS
Omalizumab has proven its efficacy in large randomized studies but also in real life practice in severe allergic asthma.
Service de pneumologie, centre de compétence pour les maladies pulmonaires rares, université Paris Diderot, hôpital Bichat, AP-HP, 46, rue Henri-Huchard, 75877 Paris cedex 18, France.
P
P
Pradère
Service de pneumologie, université Paris-Sud, hôpital de Bicêtre, AP-HP, 94270 Le Kremlin-Bicêtre, France.
G
G
Garcia
Service de pneumologie, université Paris-Sud, hôpital de Bicêtre, AP-HP, 94270 Le Kremlin-Bicêtre, France.
M
M
Humbert
Service de pneumologie, centre de compétence pour les maladies pulmonaires rares, université Paris Diderot, hôpital Bichat, AP-HP, 46, rue Henri-Huchard, 75877 Paris cedex 18, France.
M
M
Aubier
Service de pneumologie, centre de compétence pour les maladies pulmonaires rares, université Paris Diderot, hôpital Bichat, AP-HP, 46, rue Henri-Huchard, 75877 Paris cedex 18, France. Electronic address: camille.taille@aphp.fr.
C
C
Taillé
D018927:Anti-Asthmatic Agents / Q000627:therapeutic use; D000888:Antibodies, Anti-Idiotypic / Q000627:therapeutic use; D001249:Asthma / Q000188:drug therapy* / Q000453:epidemiology; D011307:Drug Prescriptions / Q000706:statistics & numerical data; D006801:Humans; D000069444:Omalizumab / Q000627:therapeutic use*; D010818:Practice Patterns, Physicians' / Q000706:statistics & numerical data / Q000639:trends; D016896:Treatment Outcome
D018927:Anti-Asthmatic Agents; D000888:Antibodies, Anti-Idiotypic; C026408:anti-IgE antibodies; D000069444:Omalizumab
Asthma; Asthme; Atopie; Atopy; Biotherapy; Biothérapie; Immunoglobulin E; Immunoglobuline E; Omalizumab